Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Abbvie Deutschland Gmbh x26 Co Kg
Abbvie Deutschland Gmbh x26 Co Kg_20131212

Abbvie Deutschland Gmbh & Co Kg patents


Recent patent applications related to Abbvie Deutschland Gmbh & Co Kg. Abbvie Deutschland Gmbh & Co Kg is listed as an Agent/Assignee. Note: Abbvie Deutschland Gmbh & Co Kg may have other listings under different names/spellings. We're not affiliated with Abbvie Deutschland Gmbh & Co Kg, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Abbvie Deutschland Gmbh & Co Kg-related inventors


Novel inhibitor compounds of phosphodiesterase type 10a

where Z1 to Z5, Ar1 to Ar5, Ra, R21, R22 and R23 are as defined in the claims.... Abbvie Deutschland Gmbh & Co Kg

Amyloid-beta binding proteins

The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.... Abbvie Deutschland Gmbh & Co Kg

Monoclonal antibodies against amyloid beta protein and uses thereof

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.... Abbvie Deutschland Gmbh & Co Kg

Novel inhibitor compounds of phosphodiesterase type 10a

wherein Y1 and Y2 are adjacent atoms in Het1, which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O,... Abbvie Deutschland Gmbh & Co Kg

Methods for treating spinal cord injury and pain

Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.... Abbvie Deutschland Gmbh & Co Kg

Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor

wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to... Abbvie Deutschland Gmbh & Co Kg

Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose

The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.... Abbvie Deutschland Gmbh & Co Kg

Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules

The present invention relates to nanocapsules which are stabilized by a bile acid or salt thereof. The nanocapsules comprise a polymeric shell formed by poly(alkyl cyanoacrylates) and/or alkoxy derivatives thereof, wherein the polymeric shell encapsulates a core comprising an active agent. The invention further relates to methods for preparing and... Abbvie Deutschland Gmbh & Co Kg

Nanoencapsulation of antigen-binding molecules

The present invention relates to nanospheres comprising a polymeric matrix and antigen-binding molecules esterase-releasably incorporated therein. The polymeric matrix is formed by poly(alkyl cyanoacrylates) and/or alkoxy derivatives thereof. The invention further relates to methods for preparing and compositions comprising such nanospheres.... Abbvie Deutschland Gmbh & Co Kg

Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.... Abbvie Deutschland Gmbh & Co Kg

Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.... Abbvie Deutschland Gmbh & Co Kg

Fused (hetero)cyclic compounds as s1p modulators

The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.... Abbvie Deutschland Gmbh & Co Kg

Antibodies against the rgm a protein and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and... Abbvie Deutschland Gmbh & Co Kg

Hexahydrodiazepinoquinolines carrying a cyclic radical

The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of... Abbvie Deutschland Gmbh & Co Kg

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment... Abbvie Deutschland Gmbh & Co Kg

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration

The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of... Abbvie Deutschland Gmbh & Co Kg

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in... Abbvie Deutschland Gmbh & Co Kg

Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use

and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions... Abbvie Deutschland Gmbh & Co Kg

Methods for treating relapsing forms of multiple sclerosis

Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat multiple sclerosis, including relapsing forms of multiple sclerosis such as relapsing-remitting multiple sclerosis or relapsing-secondary progressive multiple sclerosis.... Abbvie Deutschland Gmbh & Co Kg

Fused heterocyclic compounds as s1p modulators

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.... Abbvie Deutschland Gmbh & Co Kg

Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivaties can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.... Abbvie Deutschland Gmbh & Co Kg

Guanidine compounds and use thereof as binding partners for 5-ht5 receptors

corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of... Abbvie Deutschland Gmbh & Co Kg

Anti-aß globulomer 4d10 antibodies

The present invention relates to anti-Aβ globulomer antibodies having a binding affinity to Aβ(20-42) globulomer that is greater than the binding affinity of the antibody to Aβ(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors,... Abbvie Deutschland Gmbh & Co Kg

Formulations of nonopioid and confined opioid analgesics

The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably... Abbvie Deutschland Gmbh & Co Kg

Ager-peptides and use thereof

The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor mulitimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with... Abbvie Deutschland Gmbh & Co Kg

Oxindole derivatives carrying an amine-substituted piperidyl-azetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders.... Abbvie Deutschland Gmbh & Co Kg

Antibodies to receptor of advanced glycation end products (rage) and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for... Abbvie Deutschland Gmbh & Co Kg








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Abbvie Deutschland Gmbh & Co Kg in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Abbvie Deutschland Gmbh & Co Kg with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###